The recent J&J acquisition of Intracellular for $14.6 Billion USD highlights the excitement surrounding Neuroscience and more specifically drugs developed to treat the huge unmet need surrounding depressive disorders and dementia. As noted in this video (see above) Actinogen has a huge bank of patient data from which to appropriately design their existing and ongoing clinical trials in these areas of interest.
In May last year Professor John Harrison and Paul Rolan spoke during an Actinogen presentation of the relationship between cognitive impairment and the neurological conditions of depression, bipolar, schizophrenia, and then Parkinson's and Alzeihmer's disease. Dr Dana Hilt of Actinogen eluded to Xanamem's potential to effectively focus on executive memory, cognition, attention and many of the key drivers of such neurological conditions. Clearly Actinogen hold the view they have enough existing data to support their own belief Xanamem can halt and slow the progress of such disorders without undue side effects. With this in mind and with a renewed focus on patients with elevated Ptau, the existing and ongoing Xanamem PH 2B/3 Trial looks set to ignite the interest of many investors, given the strong demand for treatment options in this space.
Personally speaking I must say it would appear Actinogen are in the right place at the right time to capitalise on the huge unmet need in this ever increasing market segment.
DYOR Opinions only
ACW Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)